Science Education
>

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

PREPARAÇÃO DO INSTRUTOR
CONCEITOS
PROTOCOLO DO ALUNO
JoVE Journal
Medicina
É necessária uma assinatura da JoVE para visualizar este conteúdo.  Faça login ou comece sua avaliação gratuita.
JoVE Journal Medicina
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

HNE samples were procured from subjects recruited through the Cincinnati Children's Hospital Medical Center CF Research Center. All methods described here have been approved by the Institutional Review Board (IRB) of Cincinnati Children's Hospital Medical Center. Written consent was obtained from all subjects prior to testing.

1. Prepare Expansion Media and Antibiotic Media

  1. Gather media components listed in Table 1. Thaw frozen materials at room temperature and make necessary stock solutions as indicated in Table 1 under "Expansion Media".
    NOTE: Use care when handling cholera toxin, which is toxic if ingested, and is a skin, eye, and respiratory irritant. Make and combine all solutions and media under clean conditions in the biosafety cabinet.
  2. Using a 50 mL serologic pipette, remove and discard 50 mL of base medium (Dulbecco Modified Eagle Medium/F12) from one container to compensate for the addition of other materials. Pour all base media by hand into an autoclaved 1 L glass bottle.
  3. Using a 50 mL serologic pipette or 1 mL pipette as appropriate, transfer all remaining components from the "Expansion Media" section of Table 1 into the autoclaved glass bottle containing the media. Gently swirl the bottle by hand to mix.
  4. Filter media into a fresh, sterile 1 L, 0.22 µm polyethersulfone (PES) filter flask using the manufacturer's instructions and annotate with "Expansion Media" and date.
  5. Prepare Antibiotic Media. Make necessary antibiotic stock solutions as indicated in Table 1 under "Antibiotic Media."
    1. Using a 50 mL serological pipette, transfer 150 mL of Expansion Media to a fresh 250 mL autoclaved glass bottle.
    2. Using a 1 mL pipette, add all components from the "Antibiotic Media" section of Table 1 into the autoclaved glass bottle containing the media. Swirl by hand to mix until the media is uniform in appearance.
    3. Filter media into a fresh, sterile 250 mL, 0.22 µm PES filter flask using the manufacturer's instructions and annotate with "Antibiotic Media" and date.
  6. Store media at 4 °C for up to one month, discarding if cloudy, suggesting contamination.

2. Prepare Differentiation Media

  1. Gather media components listed in Table 2. Thaw frozen materials at room temperature and make necessary stock solutions as indicated in Table 2.
    NOTE: Use caution when handling retinoic acid, which is a reproductive toxin, can be toxic if swallowed, and causes skin irritation. Make, aliquot, and combine all solutions and media under clean conditions in the biosafety cabinet.
  2. Remove and discard 52 mL of the base medium from one container to compensate for the addition of other materials. Pour all base media into an autoclaved 1 L glass bottle.
  3. Using a 25 mL serological pipette or 1-mL pipette as appropriate, transfer all remaining components from Table 2 to the autoclaved glass bottle containing the media and swirl gently by hand to mix.
  4. Filter media into a fresh, sterile 1 L, 0.22 µm polyethersulfone (PES) filter flask using the manufacturer's instructions and annotate with "Differentiation Media" and date.
  5. Store media at 4 °C for up to one month, discarding if cloudy, suggesting contamination.

3. Coat Culture Dishes and Plate Feeder Fibroblasts

NOTE: Perform all steps under clean conditions in the biosafety cabinet.

  1. Mix 0.5 mL of collagen stock and 37.5 mL of sterile water in a 50 mL conical tube.
  2. Pipette 4-5 mL of collagen solution into each clean P100 culture dish, ensuring the entire surface is covered.
  3. Cover dishes with lids and incubate overnight at 37 °C and 5% CO2.
  4. In the biosafety cabinet, remove all dish lids. Swirl solution to cover dish, then aspirate.
  5. Sterilize by exposure to ultraviolet (UV) light for 1 h. Place lids back on the dishes, stack and cover dishes with aluminum foil.
  6. Store coated dishes at 4 °C for 3-6 months, re-sterilizing under UV light 15-30 min before cell culture use.
  7. 24 h before obtaining a HNE sample, sterilize a pre-coated dish and label as Mouse Embryonic Fibroblast (MEF) and the date.
  8. Add the Expansion Media to cover the plate (approximately 5 mL) with a serologic pipette.
  9. Thaw a vial of 2 x 106 irradiated MEFs in a 37 °C waterbath. As soon as the MEFs are thawed, add half of the vial (approximately 106 cells) to the dish with a 1-mL pipette, swirling by hand to disperse.
  10. Incubate at 37 °C and 5% CO2 overnight in preparation for HNE culture.
    NOTE: If necessary, steps 3.7-3.10 can be performed as late as 60 min before plating cells, though overnight is ideal.

4. Obtain and Process HNE Sample

  1. Ensure IRB-approved consent/assent is obtained for all subjects.
  2. Have patient blow nose to clear loose mucus.
  3. Visualize inferior turbinate using a rhinoscope. Ensure no lesions or polyps are present that may preclude sample collection.
  4. Collect nasal cells from the first nostril by curettage or brushing.
    1. Curettage: Bend curette at its midpoint to create a slight, ~135° angle with the apex away from the curette cup. Insert the curette into the nostril and advance the curette cup under the inferior turbinate. Gently press the curette cup against the inferior turbinate and scrape the turbinate by pulling the curette forward, repeating 3-4 times total.
    2. Brush: Pass the cytology brush below the inferior turbinate, then rotate and move the brush in-and-out slightly 4-5 times, without exiting the nostril.
  5. Place curette/brush in a 15 mL conical filled with Antibiotic Media. Repeat steps 4.3-4.4 for the other nostril, placing the curette/brush into the same conical tube.
  6. Store conical on ice until ready for processing. Ensure that the processing occurs within 4 h of sample acquisition but can occur as late as 24 h after acquisition if necessary.

5. Process and Expand HNE Cells in Dishes

NOTE: Perform all steps under clean conditions in the biosafety cabinet.

  1. Using a 1-mL pipette and media from the sample conical, wash all cells off of curettes/cytology brushes into the same conical tube. Once clean, discard curettes / brushes.
  2. Centrifuge conical at 360 x g and 4 °C for 5 min.
  3. Aspirate supernatant, taking care not to disturb the cell pellet.
  4. Re-suspend the cell pellet in 3 mL of cell detachment solution, pipetting with a 1 mL tip to homogenize the mixture.
  5. Centrifuge conical at 360 x g and 4 °C for 5 min.
  6. Repeat steps 5.3-5.5 once.
  7. Aspirate remaining supernatant, taking care not to disturb the cell pellet.
  8. Re-suspend the pellet in 1 mL of Antibiotic Media and count cells with a hemocytometer.
  9. Using a 1-mL pipette, plate cells dropwise onto the coated, fibroblast-seeded dish prepared in step 3.10. Add Antibiotic Media to fully cover the dish and disperse the cells across the surface. Label dish with contents and date and incubate at 37 °C and 5% CO2.
  10. After 48 h, ensure that the cells are attached to the culture dish. Aspirate the media and replace with enough fresh Antibiotic Media to cover the plate.
  11. Change media 3x weekly, aspirating old media with a vacuum line and Pasteur pipette, and replacing with enough fresh media to cover the plate. After 5 days on Antibiotic Media, change the media to Expansion Media, continuing to replace three times weekly.
    NOTE: Contamination risk is high in the first week of culture. Keep fresh samples in a separate incubator to minimize the risk of cross-contamination.
  12. Check the cell growth several times weekly. Once cells are approximately 70-80% confluent, proceed to passage cells.

6. Passage HNE Cells

  1. Prepare 0.1% Trypsin solution in ethylenediaminetetraacetic acid (EDTA).
    NOTE: Use caution handling trypsin, which is a skin, respiratory, and eye irritant.
    1. Weigh 15 mg of trypsin from the porcine pancreas in a conical tube.
    2. Weigh 56 mg of EDTA in a separate conical tube.
    3. In the biosafety cabinet, transfer trypsin and EDTA into an autoclaved 250 mL glass bottle. Use a small aliquot of sterile phosphate-buffered saline (PBS) to rinse the trypsin/EDTA tubes to ensure complete transfer.
    4. Add sterile PBS to bring the solution total to 150 mL. Close lid tightly.
    5. Incubate trypsin solution in a 37 °C waterbath until fully dissolved. Check every 15 min and remove promptly once dissolved.
      NOTE: Do not leave unchecked for prolonged periods of time (e.g., overnight), as trypsin in solution will denature if heated for too long.
    6. Clean bottle with 2-3 sprays of 70% ethanol and return to the biosafety cabinet.
    7. Filter 0.1% Trypsin-EDTA solution into a fresh, sterile 250 mL, 0.22 µm PES filter flask using the manufacturer's instructions and annotate with contents and date.
    8. Store trypsin-EDTA solution at 4 °C for up to one month, discarding if cloudy.
  2. Bring Differentiation Media, 0.1% Trypsin-EDTA solution, and sterile PBS to room temperature over 30 min. Clean with 70% ethanol and transfer to a clean biosafety cabinet.
  3. In the biosafety cabinet, use a vacuum line and Pasteur pipette to aspirate and discard media from tissue culture dish. Wash the dish by adding, swirling, and aspirating 5 mL of PBS using a clean serological pipette.
  4. Using a 5-mL serological pipette, add 5 mL of 0.1% Trypsin-EDTA solution to the tissue culture dish and return to the incubator at 37 °C and 5% CO2 for 5 min.
  5. Visualize cells on an inverted microscope at 4-10X. Check that the cells detach from the dish, become round, and float. Gently tap the side of the culture dish to dislodge cells, and/or re-incubate for an additional 5 min until most cells are detached.
    NOTE: Take caution to quickly remove cells once detached from the culture dish; prolonged exposure to 0.1% Trypsin-EDTA will impair cell viability.
  6. Using a 10 mL serological pipette, add 5 mL of Expansion Media to the dish and collect all liquid contents (10 mL total) into a labeled, sterile 50 mL conical tube.
  7. If cells remain adherent to the culture dish, repeat steps 6.4 through 6.6 up to two times, collecting contents in the same conical tube.
    1. If cells remain adherent to the culture dish after three rounds of Trypsin solution exposure, use a sterile cell scraper gently remove the remainder. After scraping the dish, wash the scraper and dish with 5 mL of Expansion Media and collect in the same labeled conical tube.
      NOTE: If passaging to spheroids, modify this procedure to perform a differential trypsinization. After adding trypsin solution (step 6.4.), check the dish frequently until fibroblasts have detached (typically 1-2 min), leaving only polygonal epithelial cells attached to the dish. Collect and set aside this supernatant, which can be passaged forward for expansion. Repeat steps 6.4-6.6 using the same trypsin solution, and collect only the remaining epithelial cells for spheroid culture.
  8. Centrifuge conical at 360 x g for 5 min and 4 °C. Aspirate media from conical.
  9. Resuspend cell pellet in 1 mL of Expansion Media and count cells using a hemacytometer.
  10. Once quantified, cells can be divided if necessary and either passaged forward onto a new culture dish (including preparation of fibroblast co-culture, step 3, and plating cells for expansion, steps 5.9-5.12) or cultured as spheroids (step 7).
    NOTE: If passaging to a new culture dish for expansion, a seeding density of 0.5-1 × 106 cells in a P100 dish is recommended.

7. Seeding Cells for HNE Spheroid Cultures

NOTE: Carry out all procedures in this step, other than centrifugation, in a clean biosafety cabinet.

  1. Thaw the basement membrane matrix on ice per manufacturer's instructions (100 µL per spheroid well).
    NOTE: Consider making sterile 500 µL aliquots of the basement membrane matrix on receipt; this amount will seed a single 4-well plate.
  2. Separate an appropriate number of differentially trypsinized, passaged cells (from step 6.9) for a final concentration of 500,000 cells per mL of the matrix. For a 4-well plate, use 200,000 cells. Collect in a 1.5 mL tube.
  3. Centrifuge cell and media mixture at 360 x g for 5 min at 4 °C. Completely, but carefully aspirate and discard media using a 1 mL pipette, taking care not to disturb the cell pellet.
  4. Using a 1 mL pipette tip, add 100 µL per planned well of the basement membrane matrix to the 1.5 mL tube containing the cells. Keep the tube on ice.
  5. Pipette up and down to carefully and thoroughly resuspend cells in the basement membrane matrix. Move quickly to avoid solidification of the matrix. Avoid completely emptying the pipette tip to ensure air bubbles are not introduced into the matrix/cell mix.
  6. Seed 100 µL matrix aliquots into each well of a 4-well IVF culture plate.
    1. Using a clean pair of scissors, trim off the distal 3-4 mm of a 200 µL pipette tip.
    2. Using the trimmed tip, carefully pipette 100 µL of the cell/matrix mixture into the center of each well. Pipette slowly, with the goal of making a single matrix "drop" in the center of each well. The drop should remain spherical, and should not touch the sides of the well. When moving the plate, do so carefully as to avoid disturbing these drops.
    3. Incubate the basement membrane matrix drops at 37 °C and 5% CO2 for 30 min, until solid.
    4. Carefully pipette 500 µL of Differentiation Media into each well, taking care not to disturb the matrix drop. Ensure that the media just cover the matrix drop and add more if necessary.

8. Differentiate and Mature HNE Spheroids

  1. Using a 1 mL pipette tip, gently aspirate all media from well; avoid aspirating the matrix, which will destroy spheroids in that portion of the matrix, though any spheroids left behind may remain viable.
  2. Using a fresh 1 mL pipette tip, gently add 500 µL of differentiation media to the well around the matrix. Do not touch the matrix with the pipette and avoid disturbing the matrix drop.
  3. Return spheroids to the incubator at 37 oC and 5% CO2 for ongoing growth. Repeat steps 8.1 through 8.3 three times weekly.
  4. Evaluate spheroid morphology daily under an inverted microscope at 20X. Spheroids should form within 3-5 days of plating, and reach maturity within approximately 10 days.

9. Pretreat, Stimulate, and Image HNE Spheroids for Analysis

  1. Pretreat spheroids as desired prior to imaging as previously described30.
    NOTE: For VX809 pretreatment, add 3 µM of VX809 to the media for 48-72 h prior to imaging. Mix 1 µL of 10 mM VX809 stock (see Materials Table) in 3.3 mL of media for this concentration.
  2. Change each well of spheroids to 1 mL of fresh Differentiation Media, including pretreatment (steps 8.1-8.3) before imaging spheroids.
  3. Prepare fresh stimulation drugs solutions (Forskolin, 3-isobutyl-1-methylxanthine [IBMX], VX770, and CFTR Inhibitor 172 [Inh172]) from stocks (see Materials Table). For forskolin/IBMX, add 1 µL of each stock to 98 µL of sterile water in a single labeled 1.5 mL tube. For VX770 and Inh172, add 1 µL of each stock to 99 µL of sterile water in separate labeled 1.5 mL tubes. Make a total volume allowing for 50 µL of solution for each well tested. Prepare solutions under sterile conditions in the biosafety cabinet.
  4. Transfer spheroid plate to an incubated chamber set to 37 °C and 5% CO2, mounted on an inverted microscope equipped with electronic image capture software and a mechanical stage for XY adjustment. Turn on the microscope and camera, as well as the imaging computer.
  5. Capture baseline images of spheroids in one well.
    1. Open the image capture software (Slidebook 5.5 for directions below). Once initialized, open a new file by clicking "File", then "New". Name the file accordingly and click "Save".
    2. Carefully remove the culture plate lid and center one matrix drop over the objective.
    3. Starting at the top of the matrix drop, move in a grid to find spheroids at 20x magnification with the microscope eyepiece. Focus up and down to capture the sphere at its widest point. Annotate the location of each spheroid on a map of the matrix drop to re-identify after imaging.
    4. In the software, click "Image-Capture". For Exposure, select "Manual" and enter 50 ms. Ensure other settings are appropriate (Bin Factor: 1×1, W: 512, H: 512, X and Y Offset: 0). Enter an appropriate name for each image in the "Name" box (e.g., Spheroid 1 Baseline). Click "Start" to view a live image, and "Save" to capture a baseline image.
    5. Repeat steps 9.5.1-9.5.4 until goal number is reached, or entire matrix drop is imaged.
      NOTE: Group differences can be detected with as few as 3-5 spheroids per condition, however, it has become our practice to image 10 or more spheroids per condition to increase power. Variability of the assay is demonstrated in Figure 2 of the "Representative Results" section, with samples of 8-10 spheroids per subject as an example.
  6. Stimulate spheroids.
    1. Using a 200 µL pipette, add 50 µL of the appropriate stimulation drug into the media within the well, taking care not to disturb the matrix.
      NOTE: After this 10-fold dilution (50 µL into 500 µL of media), the final drug concentration will be: forskolin 10 µM, IBMX 100 µM, VX770 1 µM, Inh172 10 µM.
    2. For cAMP only, add only forskolin/IBMX.
    3. For cAMP + VX770, add forskolin/IBMX first, then VX770 after 2 min.
    4. For inhibited conditions, add Inh172 first, then forskolin/IBMX after 2 min.
  7. Immediately after stimulation, monitor spheroid swelling by timelapse imaging for 1 h. In the software, click "Image-Capture". Click "Timelapse", and set the interval to 30 s, with a duration of 60 min. Enter an appropriate name and click "Save" to start timelapse.
    NOTE: Standard timelapse is to capture images of a single spheroid every 30 s to ensure a high-quality video. Alternatively, perform lower-magnification capture of the entire well (e.g., 4X), and fewer images captured if desired. If an automated stage is used, perform timelapse of all spheroids using predefined coordinates; otherwise, use timelapse of a subset of spheroids to provide a qualitative review of swelling and to ensure no systematic issues arise during imaging (e.g., matrix detachment from the well).
  8. Immediately upon completion of the 1 h timelapse image, capture post-stimulation images of all spheroids (per step 9.5) using the map created in step 9.5.3.
    1. Refer to pre-stimulation images to ensure the same plane of focus is used for follow-up images (the focal quality of surrounding cells, spheroids, or debris greatly facilitate this process).
    2. Save files with a paired annotation from step 9.5.4 (e.g., Spheroid 1 Post-Stimulation).
      NOTE:Complete this step immediately after the timelapse, as spheroids may continue to swell.
  9. Replace media in the imaged well with fresh Differentiation Media.
  10. Repeat steps 9.5 through 9.9 for each well/condition, adjusting stimulation drugs as indicated for experimental conditions.
  11. Once all imaging is completed, return spheroids to the incubator at 37 °C and 5% CO2.
    NOTE: Depending on the sterility of the incubated microscope chamber, post-stimulation contamination of spheroids can be quite common. Either keep imaged spheroids in a separate incubator, to minimize cross-contamination risk, or discard spheroids immediately after imaging.

10. Analyze HNE Spheroid Images

  1. Export all captured images to a format compatible with image analysis software. In the software, click "View", hover over "Export", and select "Default Views of All Images as TIFF…". Save to the hard drive or a flash drive for analysis.
    NOTE:A commercial analysis software (Table of Materials) and .tiff files perform well and are described here, though analysis can also be performed using other platforms. When naming files, staff analyzing images should be blinded to the experimental conditions, but aware of which images are paired (pre- and post-stimulation) to ensure equivalent analysis.
  2. Using analysis software, delineate the luminal area of each spheroid image and export into a data analysis software.
    1. Open analysis software. Click "File", then "Open" and navigate to the file folder containing spheroid images. Select all images for analysis and click "Open".
    2. Click "Measure" and select "Region Measurements". Within the Region Measurements dialog box, select the droptab "Configuration" and ensure "Image Name" and "Area" boxes are checked.
    3. Click " Log" and select "Open Data Log". Click "OK" on the Data Log dialogue box and name file accordingly (e.g., Condition X, Date). This will transfer all measurements to a spreadsheet.
    4. Select " Trace Region" tool button and carefully trace the lumen of the spheroid in the first image for analysis. In the Region Measurement dialogue box, click " Log Data" to log the measurement into Excel.
    5. Repeat steps 10.2.2-10.2.4 until all spheroids are analyzed.
  3. Calculate the percent change (100 * [Post-stim – Baseline] ÷ Baseline) in the luminal area from baseline for each individual spheroid image pair and compile data for analysis.

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Learning Objectives

HNEs should attach to the culture dish and form small islands of cells within 72 h of seeding; examples of good and poor island formation at one week are shown in Figure 1A and 1B, respectively. These islands should expand to cover the dish over the course of 15-30 days. Small or suboptimal samples may take longer, and often will not yield useful spheroids. Contamination with infectious agents is evidenced by deep yellow/cloudy media, failure of the cells to attach to the culture dish, and/or direct visualization of fungi/bacteria. Any contaminated cultures should be immediately discarded to avoid cross-contamination.

Within the first 3-4 days of culture in the basement membrane matrix, small cystic structures should begin to form in the matrix. These will mature over approximately 10 days into intact spheroids demonstrating a thin wall and a luminal surface. If plated at the described density, successful cultures will contain 50-100 spheroids per matrix drop. The lumens may be relatively clear (Figure 1C) or filled with cellular debris and mucus (Figure 1D); the former is more common in spheroids with wild-type CFTR (wtCFTR), and the latter in CF spheroids. Masking to delineate the luminal area of the spheroids in Figure 1C and 1D is demonstrated in Figure 1E and 1F, respectively. Examples of poorly formed/unsuccessful spheroid cultures are provided in Figure 1G and 1H.

Representative functional data for wild type and F508del CFTR homozygous HNE spheroids is shown in Figure 2A and 2B, respectively; this data is representative of >10 unique HNE samples in wild type and F508del CFTR homozygous subjects30. In short, spheroids with functional CFTR swell, while those with dysfunctional CFTR swell significantly less, or may shrink. Specifically, spheroids from subjects with wtCFTR should swell over an hour when stimulated, and should swell less or shrink if stimulated in the presence of the CFTR inhibitor Inh172. Conversely, spheroids from a subject homozygous for F508del CFTR should either shrink or swell very slightly, with increased swelling (or less shrinking) when pharmacologically corrected with the CFTR modulators VX809 and VX770. Previous analyses of spheroid reliability both within and between subjects of the same genotype demonstrate functional segregation of CFTR genotypes and modest variability in repeated measures30.

Media Component Stock Solution Amount Storage
Expansion Media
DMEM / F-12 Nutrient Mixture "Base Media" Use as is 2x 500 mL containers Store at 4 ºC up to manufacturer expiration date
Fetal Bovine Serum Use as is 50 mL Store at -20 ºC up to manufacturer expiration date
Cholera Toxin 10 mg in 1 mL of sterile water 1 µL Store stock at -20 ºC up to six months
Epidermal Growth Factor 500 µg in 1 mL of sterile water 20 µL Store stock at -20 ºC up to six months
Hydrocortisone 0.4 mg in 400 µL of sterile water Entire 400 µL aliquot Make fresh with each batch. Store powder at room temperature up to manufacturer expiration date
Adenine 24 mg in 1 mL of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at room temperature up to manufacturer expiration date
Y-27632 3.2 mg in 1 mL of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date
Antibiotic Media
Amphotericin B Use as is 1.2 mL Store at 4 ºC up to manufacturer expiration date
Ceftazidime 15 mg in 1 mL of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date
Tobramycin 15 mg in 1 mL of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date
Vancomycin 15 mg in 1 mL of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date

Table 1: Components of Expansion and Antibiotic Media.

Media Component Stock Solution Amount Storage
DMEM / F-12 Nutrient Mixture "Base Media" Use as is 2x 500 mL containers Store at 4 ºC up to manufacturer expiration date
Ultroser-G 20 mL of sterile water in a single, 20 mL bottle of lyophilized Ultroser-G Entire 20 mL aliquot Make fresh with each batch. Store powder at 4 ºC up to manufacturer expiration date
Fetal Clone II Use as is 20 mL Store at -20 ºC up to manufacturer expiration date
Pen Strep Use as is 10 mL Store at -20 ºC up to manufacturer expiration date
Bovine Brain Extract Use as is 2.48 mL Store at -20 ºC up to manufacturer expiration date
Transferrin Use as is 250 µL Store at -20 ºC up to manufacturer expiration date
Insulin Use as is 250 µL Store at -20 ºC up to manufacturer expiration date
Ethanolamine Use as is 15 µL Store at room temperature up to manufacturer expiration date
Epinephrine 2.75 mg in 1 ml of sterile water Entire 1 mL aliquot Make fresh with each batch. Store powder at 4 ºC up to manufacturer expiration date
Triiodothyronine 8.4 mg in 50 µL of DMSO Entire 50 µL aliquot Make fresh with each batch. Store powder at -20 ºC up to manufacturer expiration date
Hydrocortisone 7.24 mg in 1 mL of ethanol 1 µL Store stock at -20 ºC up to six months
Phsophoryletheanolamine 35.25 mg in 1 mL of sterile water 1 µL Store stock at -20 ºC up to six months
Retinoic Acid 3 mg in 1 mL of DMSO 1 µL Store stock at -20 ºC up to six months

Table 2: Components of Differentiation Medium.

Figure 1
Figure 1: HNE Expansion and Structural Characteristics of HNE Spheroids. Brightfield images of HNE expansion cultures taken seven days after plating demonstrate successful (white arrow, panel A) and unsuccessful (panel B) HNE colony formation on a feeder fibroblast background. Successful wtCFTR and F508del homozygous spheroids are shown in panels C and D, respectively. Masking to delineate the luminal area of spheroids from C/D is provided in panels E and F, respectively. Unsuccessful spheroid cultures are characterized by small, disorganized cellular debris (panel G) and/or disorganized clumps of cells (panel H). Scale bar = 100 µm. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Functional Characteristics of HNE Spheroids. Representative functional responses of wtCFTR spheroids from a single donor, when stimulated with forskolin/IBMX with/without the presence of the CFTR inhibitor Inh172 are shown in panel (A) Each point represents the response in a single spheroid. Representative functional responses of F508del homozygous spheroids from a single donor, when stimulated with forskolin/IBMX with/without the presence of VX809 and VX770 are shown in panel (B). Error bars = SEM. **p <0.01; ***p <0.001. Please click here to view a larger version of this figure.

List of Materials

1.5 mL Eppendorf Tube USA Scientific  4036-3204
150 mL Filter Flask Midsci  TP99150 To filter Media
15 mL Conical Tube Midsci  TP91015
1 L Filter Flask Midsci  TP99950 To filter Media
35 mm Glass-Bottom Dish MatTek Corporation P35G-0-20-C Optional
3-Isobutyl-1-Methylxanthine (IBMX) Fisher Scientific  AC228420010  Prepare a 100 mM stock solution of 22.0 mg in 1 mL of DMSO
50 mL Conical Tube Midsci   TP91050
Accutase Innovative Cell Technologies, Inc. AT-104 Cell detachment solution
Adenine Sigma-Aldrich A2786-25G See Table 1
Amphotericin B Sigma-Aldrich A9528-100MG See Table 1
Bovine Brain Extract (9mg/mL) Lonza  CC-4098 See Table 2
Ceftazidime hydrate Sigma-Aldrich C3809-1G See Table 1
Cell Scrapers 20 cm  Midsci  TP99010
CFTR Inh172 Tocris Bioscience 3430 Prepare a 10 mM stock solution of 4.0 mg in 1 mL of DMSO
Cholera Toxin B (From Vibrio cholerae) Sigma-Aldrich C8052-.5MG See Table 1
CYB-1 Medical Packaging Corporation CYB-1 Cytology brush
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D5879-500ML
Dulbecco's Modified Eagle Media (DMEM)/F12 Hepes  Life Technologies  11330-057 Base Medium; See Tables 1 and 2
Epidermal Growth Factor (Recombinant Human Protein, Animal-Origin Free) Thermo Fisher Scientific PHG6045 See Table 1
Epinephrine Sigma-Aldrich E4250-1G See Table 2
Ethanol Fisher Scientific  2701
Ethanolamine Sigma-Aldrich E0135-500ML 16.6 mM solution; See Table 2
Ethylenediaminetetraacetic Acid (EDTA) TCI America  E0084
Fetal Bovine Serum (high performance FBS) Invitrogen  10082147 See Table 1
Forskolin Sigma-Aldrich F6886-50 Prepare a 10 mM stock solution of 4.1 mg in 1 mL of DMSO
Growth Factor-Reduced Matrigel Corning, Inc. 356231 Corning Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix, Phenol Red-Free, LDEV-Free, 10 mL.
Hemacytometer Hausser Scientific 1483
Human Collagen Solution, Type I (VitroCol; 3 mg/mL) Advanced BioMatrix 5007-A Collagen solution
HyClone (aka FetalClone II)  GE Healthcare  SH30066.03HI See Table 2
Hydrocortisone StemCell Technologies 07904 See Tables 1 and 2
Insulin, human recombinant, zinc solution Life Technologies  12585014 4 mg/mL solution; see Table 2
IVF 4-Well Dish, Non-treated NUNC (via Fisher Scientific) 12566350 4-well plate for spheroids; similar well size to a 24-well plate
MEF-CF1-IRR Globalstem GSC-6001G Irradiated murine embryonic fibroblasts
Metamorph 7.7 Molecular Devices Analysis Software; https://www.moleculardevices.com/systems/metamorph-research-imaging/metamorph-microscopy-automation-and-image-analysis-software for a quote
Olympus IX51 Inverted Microscope Olympus Corporation Discontinued Imaging Microscope. Replacment: Olympus IX53, https://www.olympus-lifescience.com/pt/microscopes/inverted/ix53/  for a quote
Pen Strep Life Technologies  15140122 See Table 2
Phsophoryletheanolamine Sigma-Aldrich P0503-5G See Table 2
Retinoic Acid Sigma-Aldrich R2625-50MG See Table 2
Rhinoprobe Arlington Scientific, Inc. 96-0905 Nasal curette
Slidebook 5.5 3i, Intelligent Imaging Innovations Discontinued Imaging Software. Replacement: Slidebook 6, https://www.intelligent-imaging.com/slidebook for a quote
Sterile Phosphate Buffered Saline (PBS) Thermo Fisher Scientific 20012050
Sterile Water Sigma-Aldrich W3500-6X500ML
Tissue Culture Dish 100 Techno Plastic Products 93100 Tissue culture dish for expansion
Tobramycin Sigma-Aldrich T4014-100MG See Table 1
Transferrin (Human Transferrin 0.5 mL) Lonza  CC-4205 See Table 2
Triiodothryonine Sigma-Aldrich T6397-1G 3,3′,5-Triiodo-L-thyronine sodium salt  [T3]; See Table 2
Trypsin from Porcine Pancreas Sigma-Aldrich T4799-10G
Ultroser-G Crescent Chemical (via Fisher Scientific) NC0393024 20 mL lypophilized powder; See Table 2
Vancomycin hydrochloride from Streptomyces orientalis Sigma-Aldrich V2002-5G See Table 1
VX770 Selleck Chemicals S1144 Prepare a 1 mM stock solution of 0.4 mg in 1 mL of DMSO
VX809 Selleck Chemicals S1565 Purchase or prepare a 10 mM stock solution of 4.5 mg in 1 mL of DMSO
Y-27632 Dihydrochloride  ROCK inhibitor  Enzo LifeSciences  ALX-270-333-M025  See Table 1

Preparação do Laboratório

While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.

While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.

Procedimento

While the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drugs has revolutionized care in Cystic Fibrosis (CF), the genotype-directed therapy model currently in use has several limitations. First, rare or understudied mutation groups are excluded from definitive clinical trials. Moreover, as additional modulator drugs enter the market, it will become difficult to optimize the modulator choices for an individual subject. Both of these issues are addressed with the use of patient-derived, individualized preclinical model systems of CFTR function and modulation. Human nasal epithelial cells (HNEs) are an easily accessible source of respiratory tissue for such a model. Herein, we describe the generation of a three-dimensional spheroid model of CFTR function and modulation using primary HNEs. HNEs are isolated from subjects in a minimally invasive fashion, expanded in conditional reprogramming conditions, and seeded into the spheroid culture. Within 2 weeks of seeding, spheroid cultures generate HNE spheroids that can be stimulated with 3′,5′-cyclic adenosine monophosphate (cAMP)-generating agonists to activate CFTR function. Spheroid swelling is then quantified as a proxy of CFTR activity. HNE spheroids capitalize on the minimally invasive, yet respiratory origin of nasal cells to generate an accessible, personalized model relevant to an epithelium reflecting disease morbidity and mortality. Compared to the air-liquid interface HNE cultures, spheroids are relatively quick to mature, which reduces the overall contamination rate. In its current form, the model is limited by low throughput, though this is offset by the relative ease of tissue acquisition. HNE spheroids can be used to reliably quantify and characterize CFTR activity at the individual level. An ongoing study to tie this quantification to in vivo drug response will determine if HNE spheroids are a true preclinical predictor of patient response to CFTR modulation.

Tags